TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer.

Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

We conducted a multisite randomized trial among adults undergoing autologous or allogeneic HSCT at three academic institutions. Patients were randomly assigned to an inpatient palliative care (PC) ...

Review ITeos Therapeutics Inc Ordinary Shares (ITOS:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Review the current ITeos Therapeutics Inc Ordinary Shares (ITOS:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if ITOS is the best investment for ...